The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians

  • Ahmed M. L. Bedewy
  • Salah Showeta
  • Mostafa Hasan Mostafa
  • Lamia Saeed Kandil
Original Article


Warfarin is the most commonly used drug for chronic prevention of thromboembolic events, it also ranks high among drugs that cause serious adverse events. The variability in dose requirements has been attributed to inter-individual differences in medical, personal, and genetic factor. Cytochrome P-450 2C9 is the principle enzyme that terminates the anticoagulant effect of warfarin by catalyzing the conversion of the pharmacologically more potent S-enantiomer to its inactive metabolites. Warfarin exerts its effect by inhibition of vitamin K epoxide reductase. This protein is encoded by vitamin K epoxide reductase complex subunit 1 gene (VKORC1). The current study aimed to investigate the pharmacogenetic effect of CYP2C9 and VKORC1 gene polymorphisms on the patients response to warfarin. One hundred cases starting warfarin treatment and 20 healthy controls were enrolled. The mean daily dose of warfarin was calculated from patient’s medical records. For each patient, less than 10 % variability in warfarin dose and a target international normalized ratio (INR) within the therapeutic target range were required for at least 3 months for one of the following indications (deep vein thrombosis, pulmonary embolism, cerebrovascular stroke and myocardial infarction) prior to inclusion in the study. Tetraprimer amplification refractory mutation system PCR was performed to determine CYP2C9*2, CYP2C9*3, and the VKORC1 1639 G > A genetic polymorphisms. Plasma warfarin determination was performed using rapid fluorometric assay. Plasma warfarin concentration ranged from 2.19 to 10.98 μg/ml with a median 3.52 μg/ml. Supratherpeutic INR was observed in 11 % of the cases. Thromboembolic complications occurred in 7 % of the cases and 8 % of cases experienced major bleeding. High maintenance dose (>7 mg/day) was associated with the combined non VKORC1*2 and homozygous wild type CYP2C9 (CYP2C9*1*1) alleles, while low maintenance dose was associated with the Variant (AG + AA)/Wild (*1/*1). (p value <0.001). CYP2C9 variant was a risk factor for supratherapeutic INR in the multivariate logistic regression model. Thromboembolic complication and incidence of supratherapeutic INR were observed in patients carrying combined VKORC1 Variant (AG + AA) and CYP2C9 Variant (*2/*3). Data from our study suggest that together with clinical factors, VKORC1 and CYP2C9 polymorphisms are important contributors to warfarin dosing and may help predict adverse effects in Egyptian patients.


Warfarin Polymorphism CYP2C9 VKORC1 


Compliance with Ethical Standards

Conflict of interest

Authors declare that they have no conflict of interests.

Ethical Standards

All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Wang L, McLeod HL, Weinshilboum RM (2011) Genomics and drug response. N Engl J Med 364(12):1144–1153CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lee AYY, Peterson EA (2013) Treatment of cancer-associated thrombosis. Blood 122(14):2310–2317CrossRefPubMedGoogle Scholar
  3. 3.
    De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F et al (2013) Vitamin K antagonists in heart disease: current status and perspectives (Section III). Thromb Haemost 110(6):1087–1107PubMedGoogle Scholar
  4. 4.
    Azuma K, Ouchi Y, Inoue S (2014) Vitamin K: novel molecular mechanisms of action and its roles in osteoporosis. Geriatr Gerontol Int 14(1):1–7CrossRefPubMedGoogle Scholar
  5. 5.
    Falcone TD, Kim SS, Cortazzo MH (2011) Vitamin K: fracture prevention and beyond. PM&R 3(6):S82–S87CrossRefGoogle Scholar
  6. 6.
    Bazan N, Sabry N, Rizk A, Mokhtar S, Badary O (2014) Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism. Ir J Med Sci 183(2):161–172CrossRefPubMedGoogle Scholar
  7. 7.
    Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR (2012) Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS ONE 7(8):e44064CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Eckman MH, Rosand J, Greenberg SM, Gage BF (2009) Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 150(2):73–83CrossRefPubMedGoogle Scholar
  9. 9.
    Yin T, Miyata T (2007) Warfarin dose and the pharmacogenomics of <i> CYP2C9 </i> and <i> VKORC1 </i>—rationale and perspectives. Thromb Res 120(1):1–10CrossRefPubMedGoogle Scholar
  10. 10.
    Wei M, Ye F, Xie D, Zhu Y, Zhu J, Tao Y et al (2012) A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Thromb Haemost 107(6):1083CrossRefPubMedGoogle Scholar
  11. 11.
    Lund K, Gaffney D, Spooner R, Etherington AM, Tansey P, Tait RC (2012) Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin international normalized ratio control and bleeding rates. Br J Haematol 158(2):256–261CrossRefPubMedGoogle Scholar
  12. 12.
    D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V et al (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2):645–649CrossRefPubMedGoogle Scholar
  13. 13.
    Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadée W (2008) Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112(4):1013–1021CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Johnson J, Gong L, Whirl-Carrillo M, Gage B, Scott S, Stein C et al (2011) Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 90(4):625–629CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Miyagata Y, Nakai K, Sugiyama Y (2011) Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin. Int Heart J 52(1):44–49CrossRefPubMedGoogle Scholar
  16. 16.
    Poe BL, Haverstick DM, Landers JP (2012) Warfarin genotyping in a single PCR reaction for microchip electrophoresis. Clin Chem 58(4):725–731CrossRefPubMedGoogle Scholar
  17. 17.
    Corn M, Berberich R (1967) Rapid fluorometric assay for plasma warfarin. Clin Chem 13(2):126–131PubMedGoogle Scholar
  18. 18.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151CrossRefPubMedGoogle Scholar
  19. 19.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891CrossRefPubMedGoogle Scholar
  20. 20.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992CrossRefPubMedGoogle Scholar
  21. 21.
    Yang J, Chen Y, Li X, Wei X, Chen X, Zhang L et al (2013) Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int J Cardiol 168(4):4234–4243CrossRefPubMedGoogle Scholar
  22. 22.
    El Din M, Amin D, Ragab S, Ashour E, Mohamed M, Mohamed A (2012) Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen. Int J Lab Hematol 34(5):517–524CrossRefPubMedGoogle Scholar
  23. 23.
    Gage BF, Lesko LJ (2008) Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 25(1):45–51CrossRefPubMedGoogle Scholar
  24. 24.
    Cho H-J, Sohn K-H, Park H-M, Lee K-H, Choi B, Kim S et al (2007) Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics 8(4):329–337CrossRefPubMedGoogle Scholar
  25. 25.
    Namazi S, Azarpira N, Hendijani F, Khorshid MB, Vessal G, Mehdipour AR (2010) The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran. Clin Ther 32(6):1050–1060CrossRefPubMedGoogle Scholar
  26. 26.
    Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K et al (2007) Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120(2):181–186CrossRefPubMedGoogle Scholar
  27. 27.
    Wells P, Majeed H, Kassem S, Langlois N, Gin B, Clermont J et al (2010) A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: derivation in a sample with predominantly a history of venous thromboembolism. Thromb Res 125(6):e259–e264CrossRefPubMedGoogle Scholar
  28. 28.
    Moreau C, Bajolle F, Siguret V, Lasne D, Golmard J-L, Elie C et al (2012) Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood 119:861–867CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Zohir N, Afifi R, Ahmed A, Aly Z, Elsobekey M, Kareem H et al (2013) Role of CYP2C9, VKORC1 and calumenin genotypes in monitoring warfarin therapy: an Egyptian study. Maced J Med Sci 6(4):414–420CrossRefGoogle Scholar
  30. 30.
    Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance[ast]. Clin Pharmacol Ther 72(6):702–710CrossRefPubMedGoogle Scholar
  31. 31.
    Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A et al (2005) Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 5(3):193–202CrossRefPubMedGoogle Scholar
  32. 32.
    Lombardi R, Chantarangkul V, Cattaneo M, Tripodi A (2003) Measurement of warfarin in plasma by high performance liquid chromatography (HPLC) and its correlation with the international normalized ratio. Thromb Res 111(4):281–284CrossRefPubMedGoogle Scholar
  33. 33.
    Krajciova L, Deziova L, Petrovic R, Luha J, Turcani P, Chandoga J (2013) Frequencies of polymorphisms in CYP2C9 and VKORC1 genes influencing warfarin metabolism in Slovak population: implication for clinical practice. Bratisl Lek Listy 115(9):563–568Google Scholar
  34. 34.
    Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A et al (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358(10):999–1008CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13):1690–1698CrossRefPubMedGoogle Scholar
  36. 36.
    Ferder NS, Eby CS, Deych E, Harris JK, Ridker PM, Milligan PE et al (2010) Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost 8(1):95–100CrossRefPubMedGoogle Scholar
  37. 37.
    Aithal GP, Day CP, Kesteven PJL, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353(9154):717–719CrossRefPubMedGoogle Scholar
  38. 38.
    Ogg MS, Brennan P, Meade T, Humphries SE (1999) CYP2C9* 3 allelic variant and bleeding complications. Lancet 354(9184):1124CrossRefPubMedGoogle Scholar
  39. 39.
    Limdi N, McGwin G, Goldstein J, Beasley T, Arnett D, Adler B et al (2008) Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83(2):312–321CrossRefPubMedGoogle Scholar
  40. 40.
    Roth JA, Boudreau D, Fujii MM, Farin FM, Rettie AE, Thummel KE et al (2014) Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. Clin Pharmacol Ther 95(6):636–643CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N et al (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5(3):e1000433CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2016

Authors and Affiliations

  • Ahmed M. L. Bedewy
    • 1
    • 4
  • Salah Showeta
    • 2
  • Mostafa Hasan Mostafa
    • 2
  • Lamia Saeed Kandil
    • 3
  1. 1.Hematology Department, Medical Research InstituteAlexandria UniversityAlexandriaEgypt
  2. 2.Biotechnology Department, Institute of Graduate Studies and ResearchAlexandria UniversityAlexandriaEgypt
  3. 3.Biochemistry DepartmentPharos University in AlexandriaAlexandriaEgypt
  4. 4.AlexandriaEgypt

Personalised recommendations